Vasopharm

About:

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

Website: http://vasopharm.com

Top Investors: Bayern Kapital, 3i Group, Entrepreneurs Fund, EMBL Ventures, Hanseatic Asset Management

Description:

vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.